
RAPP Stock Forecast & Price Target
RAPP Analyst Ratings
Bulls say
Rapport Therapeutics is currently in a strong position with their lead asset RAP-219, an AMPA modulator, expected to enter Phase 3 trials in 2026 for the treatment of focal onset epilepsy and bipolar mania. Their Phase 2 results have been pulled forward to 4Q26, and they have modified their statistical analysis plan to increase sample size and provide 80% power to detect a 4-point difference on the Young Mania Rating Scale. Based on their strong clinical execution and increased confidence in RAP-219's mechanism, analysts project peak sales of $3.3B for RAP-219. However, there is still some risk involved, as competition in the epilepsy and bipolar mania markets is stiff, and delays in clinical trials due to third-party suppliers could potentially affect results.
Bears say
Rapport Therapeutics is a clinical-stage biotechnology company with a portfolio of programs focused on neurological and psychiatric disorders. While the company's pipeline appears promising, there are a few key concerns that lead to a negative outlook on its stock. Firstly, the company's lead candidate, RAP-219, is being developed for indications that are already well-served by currently available treatments. Additionally, there are concerns about potential long-term cognitive and behavioral side effects of targeting the AMPA receptor, as well as the potential for delays or errors in clinical trials. Overall, while the company's unique approach and potential for positive clinical outcomes are notable, these risks make it a risky investment at this time.
This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RAPP Analyst Forecast & Price Prediction
Start investing in RAPP
Order type
Buy in
Order amount
Est. shares
0 shares